Tango Historical Income Statement

TNGX Stock

USD 3.10 0.16 5.44%

Historical analysis of Tango Therapeutics income statement accounts such as Other Operating Expenses of 105.9 M, Research Development of 83.8 M, Cost Of Revenue of 121 M or Total Operating Expenses of 98.9 M can show how well Tango Therapeutics performed in making a profits. Evaluating Tango Therapeutics income statement over time to spot trends is a great complementary tool to traditional technical analysis and can indicate the direction of Tango Therapeutics's future profits or losses.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Tango Therapeutics latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Tango Therapeutics is a good buy for the upcoming year.

Net Income Gross Profit

Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tango Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Tango Stock please use our How to Invest in Tango Therapeutics guide.

About Tango Income Statement Analysis

Tango Therapeutics Income Statement consists of revenues and expenses along with the resulting net income or loss. It represents the profit for the accounting period attributable to Tango Therapeutics shareholders. The income statement also shows Tango investors and management if the firm made money during the period reported. The result of an income statement is the net income that is calculated after subtracting the expenses from revenue. It is essential to investors both as an absolute measure as well as earnings per share (i.e., EPS).

Tango Therapeutics Income Statement Chart

At this time, Tango Therapeutics' Interest Expense is fairly stable compared to the past year. Cost Of Revenue is likely to rise to about 121 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 1.6 M in 2024.

Selling General Administrative Total Revenue Other Operating Expenses Ebit Research Development Tax Provision

Total Revenue

Total revenue comprises all receipts Tango Therapeutics generated from the sale of its products or services. The total amount of income generated by the sale of goods or services related to the company's primary operations.

Other Operating Expenses

Other Operating Expenses is the expense which generally does not depend on sales or production quantities of Tango Therapeutics. It is also known as Tango Therapeutics overhead expenses. Typically these expenses include marketing, rent and utilities, office, leases, and other overhead cost. Expenses incurred from non-core business activities, including administrative and general expenses, but excluding costs directly related to production.

Tax Provision

The amount set aside by a company to cover any estimated taxes for the current period. It reflects the company's expected tax liabilities.

Most accounts from Tango Therapeutics' income statement are interrelated and interconnected. However, analyzing income statement accounts one by one will only give a small insight into Tango Therapeutics current financial condition. On the other hand, looking into the entire matrix of income statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Tango Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in price.

For more information on how to buy Tango Stock please use our How to Invest in Tango Therapeutics guide.At this time, Tango Therapeutics' Interest Expense is fairly stable compared to the past year. Cost Of Revenue is likely to rise to about 121 M in 2024, whereas Depreciation And Amortization is likely to drop slightly above 1.6 M in 2024.

	2021	2022	2023	2024 (projected)
Total Operating Expenses	95.2M	135.9M	150.7M	98.9M
Cost Of Revenue	2.0M	4.0M	115.2M	121.0M

Total Operating Expenses Cost Of Revenue

Tango Therapeutics income statement Correlations

	Depreciation And Amortization	Selling General Administrative	Total Revenue	Gross Profit	Other Operating Expenses	Operating Income	Ebit	Research Development	Ebitda	Cost Of Revenue	Total Operating Expenses	Income Before Tax	Total Other Income Expense Net	Net Income	Net Interest Income	Interest Income	Net Income From Continuing Ops	Reconciled Depreciation	Income Tax Expense	Non Operating Income Net Other
Depreciation And Amortization		0.89	0.15	-0.51	0.89	-0.91	-0.91	0.89	-0.91	0.52	0.9	-0.89	0.75	-0.89	0.8	0.8	-0.81	0.89	0.56	-0.77
Selling General Administrative	0.89		0.5	-0.4	0.99	-0.95	-0.95	0.99	-0.95	0.49	0.97	-0.94	0.75	-0.94	0.81	0.81	-0.93	0.96	0.75	-0.89
Total Revenue	0.15	0.5		-0.28	0.47	-0.33	-0.33	0.47	-0.33	0.45	0.4	-0.31	0.45	-0.31	0.47	0.47	-0.38	0.51	0.7	-0.3
Gross Profit	-0.51	-0.4	-0.28		-0.34	0.41	0.41	-0.32	0.4	-0.98	-0.28	0.37	-0.88	0.37	-0.81	-0.81	0.49	-0.61	-0.1	0.42
Other Operating Expenses	0.89	0.99	0.47	-0.34		-0.97	-0.97	1.0	-0.97	0.44	0.99	-0.96	0.72	-0.96	0.79	0.79	-0.91	0.93	0.8	-0.87
Operating Income	-0.91	-0.95	-0.33	0.41	-0.97		1.0	-0.97	1.0	-0.49	-0.97	1.0	-0.77	1.0	-0.85	-0.85	0.95	-0.9	-0.74	0.92
Ebit	-0.91	-0.95	-0.33	0.41	-0.97	1.0		-0.97	1.0	-0.49	-0.97	1.0	-0.77	1.0	-0.84	-0.84	0.95	-0.9	-0.74	0.92
Research Development	0.89	0.99	0.47	-0.32	1.0	-0.97	-0.97		-0.97	0.42	0.99	-0.96	0.71	-0.96	0.79	0.79	-0.91	0.92	0.81	-0.87
Ebitda	-0.91	-0.95	-0.33	0.4	-0.97	1.0	1.0	-0.97		-0.49	-0.97	1.0	-0.77	1.0	-0.84	-0.84	0.95	-0.9	-0.74	0.92
Cost Of Revenue	0.52	0.49	0.45	-0.98	0.44	-0.49	-0.49	0.42	-0.49		0.37	-0.46	0.93	-0.46	0.88	0.88	-0.58	0.67	0.28	-0.51
Total Operating Expenses	0.9	0.97	0.4	-0.28	0.99	-0.97	-0.97	0.99	-0.97	0.37		-0.97	0.67	-0.97	0.76	0.76	-0.88	0.89	0.82	-0.84
Income Before Tax	-0.89	-0.94	-0.31	0.37	-0.96	1.0	1.0	-0.96	1.0	-0.46	-0.97		-0.75	1.0	-0.83	-0.83	0.94	-0.88	-0.74	0.92
Total Other Income Expense Net	0.75	0.75	0.45	-0.88	0.72	-0.77	-0.77	0.71	-0.77	0.93	0.67	-0.75		-0.75	0.99	0.99	-0.82	0.86	0.5	-0.75
Net Income	-0.89	-0.94	-0.31	0.37	-0.96	1.0	1.0	-0.96	1.0	-0.46	-0.97	1.0	-0.75		-0.83	-0.83	0.94	-0.88	-0.74	0.92
Net Interest Income	0.8	0.81	0.47	-0.81	0.79	-0.85	-0.84	0.79	-0.84	0.88	0.76	-0.83	0.99	-0.83		1.0	-0.86	0.89	0.6	-0.8
Interest Income	0.8	0.81	0.47	-0.81	0.79	-0.85	-0.84	0.79	-0.84	0.88	0.76	-0.83	0.99	-0.83	1.0		-0.86	0.89	0.6	-0.8
Net Income From Continuing Ops	-0.81	-0.93	-0.38	0.49	-0.91	0.95	0.95	-0.91	0.95	-0.58	-0.88	0.94	-0.82	0.94	-0.86	-0.86		-0.91	-0.61	0.99
Reconciled Depreciation	0.89	0.96	0.51	-0.61	0.93	-0.9	-0.9	0.92	-0.9	0.67	0.89	-0.88	0.86	-0.88	0.89	0.89	-0.91		0.63	-0.86
Income Tax Expense	0.56	0.75	0.7	-0.1	0.8	-0.74	-0.74	0.81	-0.74	0.28	0.82	-0.74	0.5	-0.74	0.6	0.6	-0.61	0.63		-0.53
Non Operating Income Net Other	-0.77	-0.89	-0.3	0.42	-0.87	0.92	0.92	-0.87	0.92	-0.51	-0.84	0.92	-0.75	0.92	-0.8	-0.8	0.99	-0.86	-0.53

Click cells to compare fundamentals

Tango Therapeutics Account Relationship Matchups

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

C	Citigroup
GM	General Motors
F	Ford Motor

Additional Tools for Tango Stock Analysis

When running Tango Therapeutics' price analysis, check to measure Tango Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Tango Therapeutics is operating at the current time. Most of Tango Therapeutics' value examination focuses on studying past and present price action to predict the probability of Tango Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Tango Therapeutics' price. Additionally, you may evaluate how the addition of Tango Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Tango Historical Income Statement

About Tango Income Statement Analysis

Tango Therapeutics Income Statement Chart

Total Revenue

Other Operating Expenses

Tax Provision

Tango Therapeutics income statement Correlations

Tango Therapeutics Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Also Currently Popular

Additional Tools for Tango Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Depreciation And Amortization	Interest Expense
Selling General Administrative	Total Revenue
Gross Profit	Other Operating Expenses
Operating Income	Ebit
Research Development	Ebitda
Cost Of Revenue	Total Operating Expenses
Income Before Tax	Total Other Income Expense Net
Net Income Applicable To Common Shares	Net Income
Tax Provision	Net Interest Income
Interest Income	Net Income From Continuing Ops
Reconciled Depreciation	Income Tax Expense
Non Operating Income Net Other

Research Development	+ 1.0	Other Operating Expenses
Ebit	+ 1.0	Operating Income
Ebitda	+ 1.0	Operating Income
Income Before Tax	+ 1.0	Operating Income
Net Income	+ 1.0	Operating Income
Ebitda	+ 1.0	Ebit

Cost Of Revenue	- 0.98	Gross Profit
Net Income	- 0.97	Total Operating Expenses
Income Before Tax	- 0.97	Total Operating Expenses
Total Operating Expenses	- 0.97	Ebitda
Ebitda	- 0.97	Research Development
Total Operating Expenses	- 0.97	Ebit